Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
radiopharmaceutical
|
| gptkbp:activeIngredient |
samarium-153 lexidronam
|
| gptkbp:approvedBy |
gptkb:FDA
1997 |
| gptkbp:ATCCode |
V10BX02
|
| gptkbp:chemicalFormula |
C6H6NNaO8.153Sm
|
| gptkbp:containsRadioisotope |
samarium-153
|
| gptkbp:halfLife |
46.3 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Quadramet
|
| gptkbp:indication |
bone pain from metastatic cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
Cytogen
|
| gptkbp:mechanismOfAction |
targets bone tissue with increased turnover
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea injection site reactions myelosuppression |
| gptkbp:usedFor |
pain relief in bone metastases
|
| gptkbp:bfsParent |
gptkb:Samarium-153
|
| gptkbp:bfsLayer |
8
|